Name: Juvmo (tavapadon) in Parkinson's disease: Prevalence of Parkinson's disease
Published: 2026-09-27T21:44:59-04:00

Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of Parkinson's disease

7 evidence topics · 5 sources

United States prevalence among adults aged 45 years and older, with projections to 2030

“Using our age- and sex-specific meta-estimates from California, Minnesota, and Ontario and the US population structure from 2010, we estimate the overall prevalence of PD among those aged ≥45 years to be 572 per 100,000 (95% confidence interval 537–614) that there were 680,000 individuals in the US aged ≥45 years with PD in 2010 and that that number will rise to approximately 930,000 in 2020 and 1,238,000 in 2030 based on the US Census Bureau population projections.” (opens the source at this quote in a new tab)

United States prevalence by sex

“For females, the prevalence was 488 (444–543), and for males 667 (612–732).” (opens the source at this quote in a new tab)
“The estimates were higher in men than in women and rose with age in both sexes.” (opens the source at this quote in a new tab)

Regional variation in North American prevalence

“We find this suggestive that—even within North America—the prevalence of PD that has come to medical attention does vary by region.” (opens the source at this quote in a new tab)
“As previously mentioned, analysis of the Medicare nationwide database found a higher prevalence in Whites and Hispanics than in Black or Asian individuals.” (opens the source at this quote in a new tab)

Prevalence by age

“In a meta-analysis of four North American populations, prevalence increased from less than 1 percent of men and women aged 45–54 years to 4 percent of men and 2 percent of women aged 85 or older” (opens the source at this quote in a new tab)

Diagnosed prevalence in the United States, 2017, with projection to 2037

“We estimated that 1.04 million individuals in the U.S. have been diagnosed with PD in 2017, with about 919,000 (89%) eligible for Medicare (91% age ≥65; 9% <65).” (opens the source at this quote in a new tab)
“PD was more prevalent in the ≥65 population (16.9 cases vs. 0.7 per 1,000 population), and more prevalent in men (595,000 males vs. 443,000 females).” (opens the source at this quote in a new tab)
“Projected PD prevalence will be more than 1.6 million with projected total economic burden surpassing $79 billion by 2037.” (opens the source at this quote in a new tab)

Global prevalence, 1990 to 2016

“In 2016, 6·1 million (95% UI 5·0–7·3) individuals worldwide had Parkinson's disease, of whom 2·9 million (47·5%) were women and 3·2 million (52·5%) were men.” (opens the source at this quote in a new tab)
“The number of individuals with Parkinson's disease in 2016 was 2·4 times higher than in 1990 (2·5 million, 95% UI 2·0–3·0).” (opens the source at this quote in a new tab)
“Neurological disorders are now the leading source of disability in the world, and Parkinson's disease is the fastest growing of these disorders.” (opens the source at this quote in a new tab)

Global prevalence projected to 2050

“25.2 (95% uncertainty interval 21.7 to 30.1) million people were projected to be living with Parkinson’s disease worldwide in 2050, representing a 112% (95% uncertainty interval 71% to 152%) increase from 2021.” (opens the source at this quote in a new tab)
“Population ageing (89%) was predicted to be the primary contributor to the growth in cases from 2021 to 2050, followed by population growth (20%) and changes in prevalence (3%).” (opens the source at this quote in a new tab)
“The regions with the highest increase in all age prevalence were estimated to be North Africa and the Middle East (145%, 99% to 190%), South Asia (135%, 122% to 194%), and South East Asia (131%, 89% to 151%), whereas Australasia (39%, 22% to 62%) and high income North America (18%, 10% to 50%) were forecasted to have the lowest rise.” (opens the source at this quote in a new tab)